Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib Switch for Chronic Low-Grade AEs in CML-CP
NCT02115386Phase 3Terminated
- Sponsor
- Novartis
- Start
- Dec 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Novartis. Started Dec 2015; status: terminated.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02115386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02115386.